{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:50:28Z","timestamp":1761745828230,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Gaucher Disease (GD) is a condition resulting from an autosomal recessive inheritance pattern, characterized by a deficiency of the lysosomal enzyme beta-glucocerebrosidase. This leads to the accumulation of glucocerebroside and other glycolipids in multiple tissues, causing damage to various organ systems. The diagnosis of GD can be challenging due to its heterogeneity, non-specific symptoms, and variability across different geographic regions and age groups. Although GD is suspected based on symptoms or signs, the diagnosis is confirmed through the measurement of deficient b-glucocerebrosidase activity and the identification of biallelic pathogenic variants in the GBA gene. Intravenous enzyme replacement therapy (ERT) is recommended for GD patients. In this paper, we report a case of a 2-year and 8-month-old girl with massive splenomegaly and radiological finding of hepatic gaucheroma, in whom a genetic study showed homozygous mutation on the GBA gene at c.1448T&gt;C (p.Leu483Pro) and certified the diagnosis of GD. This patient represents the youngest child reported to have gaucheroma and also the first one presenting with gaucheroma at the diagnosis and not during the follow up, highlighting that GD should be routinely included in the differential diagnosis of children presenting with splenomegaly and hepatomegaly, taking into account that the early start of ERT can change the natural history of the disease-preventing serious complications.<\/jats:p>","DOI":"10.3390\/children10050869","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:49:51Z","timestamp":1683888591000},"page":"869","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pediatric Gaucher Disease Presenting with Massive Splenomegaly and Hepatic Gaucheroma"],"prefix":"10.3390","volume":"10","author":[{"given":"Gianluca","family":"Boss\u00f9","sequence":"first","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pedretti","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Bertolini","sequence":"additional","affiliation":[{"name":"Unit of Radiologic Sciences, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2022.03.001","article-title":"The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?","volume":"136","author":"Weinreb","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/pbc.25165","article-title":"Early diagnosis of Gaucher disease in pediatric patients: Proposal for a diagnostic algorithm","volume":"61","author":"Andria","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"doi-asserted-by":"crossref","unstructured":"Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., and Brassier, A. (2017). A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int. J. Mol. Sci., 18.","key":"ref_3","DOI":"10.3390\/ijms18020441"},{"doi-asserted-by":"crossref","unstructured":"Suttorp, M., and Classen, C.F. (2021). Splenomegaly in Children and Adolescents. Front. Pediatr., 9.","key":"ref_4","DOI":"10.3389\/fped.2021.704635"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00431-012-1771-z","article-title":"Revised recommendations for the management of Gaucher disease in children","volume":"172","author":"Kaplan","year":"2013","journal-title":"Eur. J. Pediatr."},{"doi-asserted-by":"crossref","unstructured":"Dinur, T., Bauer, P., Beetz, C., Kramp, G., Cozma, C., Iura\u0219cu, M.I., Becker-Cohen, M., Istaiti, M., Rolfs, A., and Zimran, A. (2022). Gaucher disease diagnosis using Lyso-Gb1 on dry blood spot samples: Time to change the paradigm?. Int. J. Mol. Sci., 23.","key":"ref_6","DOI":"10.3390\/ijms23031627"},{"doi-asserted-by":"crossref","unstructured":"Dardis, A., Michelakakis, H., Rozenfeld, P., Fumic, K., Wagner, J., Pavan, E., Revel-Vilk, S., Hughes, D., Cox, T., and Aertset, J. (2022). Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1. Orphanet J. Rare Dis., 17.","key":"ref_7","DOI":"10.1186\/s13023-022-02573-6"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease","volume":"68","author":"Biegstraaten","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bcmd.2016.10.018","article-title":"Gaucheromas: When macrophages promote tumor formation and dissemination","volume":"68","author":"Ivanova","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/8904_2016_562","article-title":"Rare case of hepatic gaucheroma in a child on enzyme replacement therapy","volume":"32","author":"Korula","year":"2017","journal-title":"JIMD Rep."},{"doi-asserted-by":"crossref","unstructured":"Tseng, S.Y., Niu, D.M., Chu, T.H., Yeh, Y.C., Huang, M.H., Yang, T.F., Liao, H.C., Chiang, C.C., Ho, H.C., and Soong, W.J. (2019). Very rare condition of multiple Gaucheroma: A case report and review of the literature. Mol. Genet. Metab. Rep., 20.","key":"ref_11","DOI":"10.1016\/j.ymgmr.2019.100473"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ymgme.2021.06.009","article-title":"Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma","volume":"133","author":"Ramaswami","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00247-002-0761-0","article-title":"Mesenteric mass in a young girl\u2014An unusual site for Gaucher\u2019s disease","volume":"32","author":"Lim","year":"2002","journal-title":"Pediatr. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/MPH.0b013e31820af6a8","article-title":"Imaging findings in pediatric type 1 Gaucher disease: What the clinician needs to know","volume":"33","author":"Green","year":"2011","journal-title":"J. Pediatr. Hematol.\/Oncol."},{"doi-asserted-by":"crossref","unstructured":"Kong, W., Lu, C., Ding, Y., and Meng, Y. (2022). Update of treatment for Gaucher disease. Eur. J. Pharmacol., 926.","key":"ref_15","DOI":"10.1016\/j.ejphar.2022.175023"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jimd.12235","article-title":"The definition of neuronopathic Gaucher disease","volume":"43","author":"Schiffmann","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_17","first-page":"72","article-title":"Gaucher disease: The metabolic defect, pathophysiology, phenotypes and natural history","volume":"12","author":"Baris","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","article-title":"Recent advances in the diagnosis and management of Gaucher disease","volume":"13","author":"Gary","year":"2018","journal-title":"Expert Rev. Endocrinol. Metab."},{"unstructured":"(2023, February 03). Phase 1\/2 Clinical Trial of PR001 in Infants with Type 2 Gaucher Disease (PROVIDE), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04411654.","key":"ref_19"},{"unstructured":"(2023, February 03). Venglustat in Combination with Cerezyme in Adult Patients with Gaucher Disease Type 3 with Venglustat Monotherapy Extension, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02843035.","key":"ref_20"},{"unstructured":"(2023, February 03). Safety and Efficacy of Eliglustat with or without Imiglucerase in Pediatric Patients with Gaucher Disease (GD) Type 1 and Type 3, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03485677.","key":"ref_21"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease","volume":"71","author":"Charrow","year":"2007","journal-title":"Clin. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcmd.2016.10.011","article-title":"Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients","volume":"68","author":"Machaczka","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_27","first-page":"47","article-title":"Large Mesenteric Gaucheroma Responds to Substrate Reduction Therapy: A New Management of Gaucheromas","volume":"11","author":"Yano","year":"2020","journal-title":"J. Pediatr. Genet."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/10\/5\/869\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:33:36Z","timestamp":1760124816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/10\/5\/869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["children10050869"],"URL":"https:\/\/doi.org\/10.3390\/children10050869","relation":{},"ISSN":["2227-9067"],"issn-type":[{"type":"electronic","value":"2227-9067"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}